Arrowhead Pharmaceuticals (ARWR)
(Delayed Data from NSDQ)
$24.08 USD
+0.15 (0.63%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $24.09 +0.01 (0.04%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMArrowhead Research (ARWR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$48.86 | $71.00 | $19.00 | 104.18% |
Price Target
Based on short-term price targets offered by 14 analysts, the average price target for Arrowhead Research comes to $48.86. The forecasts range from a low of $19.00 to a high of $71.00. The average price target represents an increase of 104.18% from the last closing price of $23.93.
Analyst Price Targets (14)
Broker Rating
Arrowhead Research currently has an average brokerage recommendation (ABR) of 1.73 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 15 brokerage firms. The current ABR compares to an ABR of 1.73 a month ago based on 15 recommendations.
Of the 15 recommendations deriving the current ABR, nine are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 60% and 6.67% of all recommendations. A month ago, Strong Buy made up 60%, while Buy represented 6.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 9 | 9 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 5 | 5 | 5 | 5 | 5 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.73 | 1.73 | 1.73 | 1.73 | 1.73 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/12/2024 | B. Riley Securities | Mayank Mamtani | Strong Buy | Strong Buy |
8/11/2024 | Chardan Capital Markets | Keay T Nakae | Strong Buy | Strong Buy |
7/16/2024 | Piper Sandler | Edward A Tenthoff | Strong Buy | Strong Buy |
6/5/2024 | Goldman Sachs | Andrea Tan | Not Available | Hold |
6/3/2024 | SVB Securities | Mani Foroohar | Hold | Hold |
5/16/2024 | Cantor Fitzgerald & Co | Prakhar Agrawal | Strong Buy | Strong Buy |
5/13/2024 | H.C. Wainwright & Co. | Patrick Trucchio | Strong Buy | Strong Buy |
5/8/2024 | UBS | Eliana Merle | Not Available | Strong Buy |
4/1/2024 | Cowen & Co. | Brendan Smith | Strong Buy | Strong Buy |
2/8/2024 | Not Identified | Not Identified | Hold | Hold |
2/7/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
1/2/2024 | Not Identified | Not Identified | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.73 |
ABR (Last week) | 1.73 |
# of Recs in ABR | 15 |
Average Target Price | $48.86 |
LT Growth Rate | 5.50% |
Industry | Medical - Drugs |
Industry Rank by ABR | 97 of 253 |
Current Quarter EPS Est: | -0.60 |